TRIB TRINITY BIOTECH PLC

Nasdaq trinitybiotech.com


$ 1.03 $ -0.01 (-0.63 %)    

Tuesday, 14-Oct-2025 17:10:00 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 1.0732
$ 1.05
$ 1.01 x 7
$ 1.09 x 827
$ 1.03 - $ 1.08
$ 1.00 - $ 17.20
70,168
na
19.27M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 trinity-biotech-regains-nasdaq-compliance

Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and dia...

 trinity-biotech-announces-clinical-trial-results-demonstrating-technical-breakthrough-and-de-risking-commercial-pathway-for-its-next-gen-continuous-glucose-monitoring-technology-called-cgm

Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes managemen...

 mhra-says-received-reports-describing-positive-bias-in-hba1c-results-delivered-by-trinity-biotech-premier-hb9210-hba1c-analyser-says-positive-bias-in-hba1c-results-resulted-in-patients-being-incorrectly-diagnosed-as-pre-diabetic-or-diabetic-trinity-biotech-committed-to-updating-intended-use-statement-in-the-instructions-for-use

https://www.gov.uk/drug-device-alerts/trinity-biotech-premier-hb9210-hba1c-analyser-risk-of-positive-bias-and-updates-to-instru...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION